Evidence map›Paper›PMID 23641861›Full record

ArticleAntioxidants & redox signaling2014

Protective role of DNJ-27/ERdj5 in Caenorhabditis elegans models of human neurodegenerative diseases.

Fernando Muñoz-Lobato, María Jesús Rodríguez-Palero, Francisco José Naranjo-Galindo, Freya Shephard, Christopher J Gaffney, Nathaniel J Szewczyk, Shusei Hamamichi, Kim A Caldwell, Guy A Caldwell, Chris D Link and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Antioxidants & redox signaling, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 58 citations in OpenAlex.

  1. A Brief Review on Caenorhabditis elegans Role in Modelling Neurodegenerative Disease.Central nervous system agents in medicinal chemistry · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Frontiers in aging · 2022
    Review
  10. CaScientific reports · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Pasteurized Orange Juice Rich in Carotenoids ProtectsOxidative medicine and cellular longevity · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Fernando Muñoz-Lobato1 Centro Andaluz de Biología del Desarrollo (CABD-CSIC), Depto. de Fisiología, Anatomía y Biología Celular, Universidad Pablo de Olavide , Sevilla, Spain .
María Jesús Rodríguez-Palero
Francisco José Naranjo-Galindo
Freya Shephard
Christopher J Gaffney
Nathaniel J Szewczyk
Shusei Hamamichi
Kim A Caldwell
Guy A Caldwell
Chris D Link
Antonio Miranda-Vizuete
Centro Andaluz de Biología del Desarrollo · ESUniversity of Alabama · USUniversity of Nottingham · GBUniversity of Colorado Boulder · US

Funding

TRANSGENIC C. ELEGANS AS AMYLOID DISEASE MODELR01AG012423 · NIA · UNIVERSITY OF COLORADO AT BOULDER · PI LINK, CHRISTOPHER D. · 1996 to 2012
$3.6M
Gene Networks Regulating Muscle Protein DegradationR01AR054342 · NIAMS · UNIVERSITY OF NOTTINGHAM · PI SZEWCZYK, NATHANIEL J. · 2007 to 2010
$902k
Medical Research Council MR/K00414X/1NIAMS NIH HHS AR-05342NIAMS NIH HHS R01 AR054342NIA NIH HHS R01 AG012423
6 · The paper itself

Abstract

aimsCells have developed quality control systems for protection against proteotoxicity. Misfolded and aggregation-prone proteins, which are behind the initiation and progression of many neurodegenerative diseases (ND), are known to challenge the proteostasis network of the cells. We aimed to explore the role of DNJ-27/ERdj5, an endoplasmic reticulum (ER)-resident thioredoxin protein required as a disulfide reductase for the degradation of misfolded proteins, in well-established Caenorhabditis elegans models of Alzheimer, Parkinson and Huntington diseases.

resultsWe demonstrate that DNJ-27 is an ER luminal protein and that its expression is induced upon ER stress via IRE-1/XBP-1. When dnj-27 expression is downregulated by RNA interference we find an increase in the aggregation and associated pathological phenotypes (paralysis and motility impairment) caused by human β-amyloid peptide (Aβ), α-synuclein (α-syn) and polyglutamine (polyQ) proteins. In turn, DNJ-27 overexpression ameliorates these deleterious phenotypes. Surprisingly, despite being an ER-resident protein, we show that dnj-27 downregulation alters cytoplasmic protein homeostasis and causes mitochondrial fragmentation. We further demonstrate that DNJ-27 overexpression substantially protects against the mitochondrial fragmentation caused by human Aβ and α-syn peptides in these worm models. INNOVATION: We identify C. elegans dnj-27 as a novel protective gene for the toxicity associated with the expression of human Aβ, α-syn and polyQ proteins, implying a protective role of ERdj5 in Alzheimer, Parkinson and Huntington diseases.

conclusionOur data support a scenario where the levels of DNJ-27/ERdj5 in the ER impact cytoplasmic protein homeostasis and the integrity of the mitochondrial network which might underlie its protective effects in models of proteotoxicity associated to human ND.

Indexed as

alpha-SynucleinAmyloid beta-PeptidesAnimalsAnimals, Genetically ModifiedAutophagyCaenorhabditis elegansCaenorhabditis elegans ProteinsDisease Models, AnimalEndoplasmic Reticulum-Associated DegradationGene ExpressionGene Expression RegulationHSP40 Heat-Shock ProteinsHumansMitochondriaMolecular ChaperonesNeurodegenerative Diseasesalpha-SynucleinAmyloid beta-PeptidesCaenorhabditis elegans ProteinsDNAJC10 protein, humanHSP40 Heat-Shock ProteinsMolecular ChaperonesPeptidespolyglutamineProteasome Endopeptidase Complex

Identifiers

PMID23641861
PMCPMC3887457
OpenAlexW2064329597

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.